Yunping Lu
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism 7
- Cancer, Hypoxia, and Metabolism 6
- Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 7
- Cell death mechanisms and regulation 7
- Redox biology and oxidative stress 6
- Oncology top 10%
- Peptidase Inhibition and Analysis 6
- Reproductive Medicine top 10%
- Cell Biology top 10%
-
- Virus-based gene therapy research 8
-
- Cancer Research and Treatments 8
- Partner nations
- ChinaUnited StatesRussia
In The Last Decade
Yunping Lu
73 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 91
- Cancer Research 324
- Molecular Biology 762
- Oncology 287
- Reproductive Medicine 68
- Cell Biology 125
Countries citing papers authored by Yunping Lu
This map shows the geographic impact of Yunping Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunping Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunping Lu more than expected).
Fields of papers citing papers by Yunping Lu
This network shows the impact of papers produced by Yunping Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunping Lu. The network helps show where Yunping Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yunping Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2023 | 2 | |
| 3 | 2021 | 13 | |
| 4 | 2021 | 5 | |
| 5 | A Novel blaCTX-M-65-Harboring IncHI2 Plasmid pE648CTX-M-65 Isolated from a Clinical Extensively-Drug-Resistant Escherichia coli ST648 | 2020 | 1 |
| 6 | HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma | 2020 | 0 |
| 7 | 2020 | 12 | |
| 8 | 2012 | 1 | |
| 9 | 2010 | 11 | |
| 10 | 2010 | 14 | |
| 11 | 2009 | 30 | |
| 12 | 2008 | 23 | |
| 13 | 2008 | 3 | |
| 14 | 2007 | 1 | |
| 15 | [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms]. | 2007 | 5 |
| 16 | [Expression of Ezrin and E-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis]. | 2006 | 17 |
| 17 | 2006 | 27 | |
| 18 | 2006 | 9 | |
| 19 | 2005 | 38 | |
| 20 | [Lipid-lowering effect of pravastatin on glomerulosclerosis protection and treatment]. | 1997 | 1 |
About Yunping Lu
Yunping Lu is a scholar working on Cancer Research, Biotechnology, Molecular Biology, Oncology and Genetics, having authored 77 papers that have together received 1.1k indexed citations. Recurring topics across this work include Virus-based gene therapy research (8 papers), Cancer Research and Treatments (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Cell death mechanisms and regulation (7 papers), Cancer, Lipids, and Metabolism (7 papers), Peptidase Inhibition and Analysis (6 papers), Redox biology and oxidative stress (6 papers) and Cancer, Hypoxia, and Metabolism (6 papers). The work is most often cited by research in Cancer Research (324 citations), Molecular Biology (762 citations), Oncology (287 citations), Reproductive Medicine (68 citations) and Cell Biology (125 citations). Yunping Lu has collaborated with scholars based in China, United States and Russia. Frequent co-authors include Ding Ma, Gang Chen, Jianfeng Zhou, Shixuan Wang, Shixuan Wang, Danhui Weng, Hui Xing, Ding Ma, Gang Chen and Qinglei Gao. Their work appears in journals such as Cancer Letters, Clinical Cancer Research, Oncology Reports, Gynecologic Oncology and Cancer Management and Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.